Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance?

查看全文 作　　者：Sho [1]Suzuki;Mitsuru [1]Esaki;Chika [1]Kusano;Hisatomo [1]Ikehara;Takuji [1]Gotoda

机构地区：[1]Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine

出　　处：《World Journal of Gastroenterology》索引2019年第25卷第16期,共6页

摘　　要：Helicobacter pylori(H. pylori) antimicrobial resistance is an urgent, global issue. In2017, the World Health Organization designated clarithromycin-resistant H.pylori as a high priority bacterium for antibiotic research and development. In addition to clarithromycin, resistance to metronidazole and fluoroquinolones has also increased worldwide. Recent international guidelines for management of H.pylori infection recommend bismuth or non-bismuth quadruple therapy for 14 d as a first-line treatment for H. pylori in areas of high clarithromycin and/or metronidazole resistance. Although these treatment regimens provide acceptable H. pylori eradication rates, the regimens used should not contribute to future resistance of H. pylori to antimicrobials. Moreover, these regimens can promote resistance, due to prolonged therapy with multiple antibiotics. A new strategy that can eradicate H. pylori as well as reduce the antibiotics used is required to prevent future antimicrobial resistance in H. pylori. Dual-therapy with vonoprazan and amoxicillin could be a breakthrough for H. pylori eradication in an era of growing antimicrobial resistance. This regimen may provide a satisfactory eradication rate of H. pylori and also minimize antimicrobial resistance due to single antibiotic use and the strong inhibitory effect of vonoprazan on gastric acid secretion. 关键词：HELICOBACTER PYLORI Antibiotic RESISTANCE ANTIMICROBIAL RESISTANCE Dual therapy Vonoprazan

相关文献

参考文献（39）
引证文献（24）
耦合文献（0）

参考文献(39)

引证文献(24)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance?

参考文献(39)

引证文献(24)

用户提示